SCHEMBL17003710

SCHEMBL17003710

COC(=O)c1cccc(C2CC2C(=O)O)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DGAT2 Q96PD7 2/20 0.52
▸ MGAT2 Q10469 1/20 0.52
▸ ALDH1A1 P00352 2/20 0.49
▸ HPGD P15428 1/20 0.49
▸ TSHR P16473 1/20 0.49
▸ RAB9A P51151 1/20 0.47
▸ FFAR1 O14842 2/20 0.46
▸ GAA P10253 1/20 0.46
▸ LOXL2 Q9Y4K0 1/20 0.45
▸ SLC9A1 P19634 1/20 0.45
▸ KDM1A O60341 1/20 0.45
▸ MAOA P21397 1/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ TDP1 Q9NUW8 1/20 0.45
▸ ITGB3 P05106 1/20 0.44
▸ ITGB1 P05556 1/20 0.44
▸ ITGAV P06756 1/20 0.44
▸ ITGA2B P08514 1/20 0.44
▸ ITGB5 P18084 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24890703 1.00 DGAT2 (0.52) DGAT2MGAT2ALDH1A1HPGDTSHR
SCHEMBL21501044 1.00 DGAT2 (0.52) DGAT2MGAT2ALDH1A1HPGDTSHR
SCHEMBL22752210 1.00 DGAT2 (0.52) DGAT2MGAT2ALDH1A1HPGDTSHR
SCHEMBL21501062 1.00 DGAT2 (0.52) DGAT2MGAT2ALDH1A1HPGDTSHR
SCHEMBL17002715 1.00 DGAT2 (0.52) DGAT2MGAT2ALDH1A1HPGDTSHR
SCHEMBL28885393 0.90 DGAT2 (0.48) DGAT2MGAT2ALDH1A1HPGDTSHR
SCHEMBL22887359 0.86 TSHR (0.55) DGAT2MGAT2ALDH1A1HPGDTSHR
SCHEMBL24411136 0.86 TSHR (0.55) DGAT2MGAT2ALDH1A1HPGDTSHR
SCHEMBL24890704 0.84 DGAT2 (0.44) DGAT2MGAT2ALDH1A1HPGDTSHR
SCHEMBL17003109 0.84 DGAT2 (0.44) DGAT2MGAT2ALDH1A1HPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2907802-B1 CYCLOPROPANAMINE COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICALS CO (JP) 2019-08-07 — — EP disclosed
US-9751885-B2 Cyclopropanamine compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-09-05 — — US disclosed
CN-105051005-A Cyclopropylamine compound and use thereof TAKEDA PHARMACEUTICAL 2015-11-11 — — CN disclosed
US-20150266881-A1 CYCLOPROPANAMINE COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-09-24 — — US disclosed
EP-2907802-A1 CYCLOPROPANAMINE COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2015-08-19 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150266881-A1 CYCLOPROPANAMINE COMPOUND AND USE THEREOF BHMT, HNMT, KDM1A DGAT2 3442/4885MGAT2 2664/4885ALDH1A1 392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback